Results 31 to 40 of about 315,728 (345)
Frontiers in Immunology, 2020 Immune responses to protein and peptide drugs can alter or reduce their efficacy and may be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical measure of protein therapeutic immunogenicity, T cell epitopes in the ...
Vibha Jawa +7 more
doaj +1 more source
Journal of Pharmaceutical Analysis, 2022 Inducible T-cell costimulator (ICOS), a homodimeric protein expressed on the surface of activated T-cells, is being investigated as a potential therapeutic target to treat various cancers.
Kevin McKinski +5 more
doaj
Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]
PLoS Computational Biology, 2013 T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis +7 more
doaj +1 more source
npj Vaccines, 2021 As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to underpin decision-making. We here report a systematic literature review and meta-analysis of Phase I/II/III human trials and non-human primates (NHP) studies ...
I. McDonald +4 more
semanticscholar +1 more source
Immunogenicity of Cas9 Protein [PDF]
Journal of Pharmaceutical Sciences, 2020 Clustered regularly interspaced short palindromic repeats (CRISPR) form the adaptive immune system in archaea and bacteria and have been modified for genome engineering in eukaryotic cells. CRISPR systems contain 2 components, a single-guide RNA, which is a short RNA composed of a 20 nucleotide sequence that targets specific sites in the genomic DNA ...
Mehta, Aditi, Merkel, Olivia M.
openaire +3 more sources
Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
Nature, 2021 Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine1,2, European health authorities recommended that patients under the age of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 ...
B. Pozzetto +37 more
semanticscholar +1 more source
Journal of Immunology Research, 2016 Numbers of biotherapeutic products in development have increased over past decade. Despite providing significant benefits to patients with unmet needs, almost all protein-based biotherapeutics could induce unwanted immunogenicity, which result in a loss ...
Sam Song +3 more
doaj +1 more source
Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Frontiers in Immunology, 2021 There is a significant research gap in meta-analysis on the efficacy and safety of coronavirus disease 2019 (COVID-19) vaccines. This study analyzed the efficacy of COVID-19 vaccines. Published phase I, phase II, and phase III trials analyzing safety and
N. Sharif +3 more
semanticscholar +1 more source
Immunogenicity of Rhinoviruses
Experimental Biology and Medicine, 1970 SummaryUniformly successful production of rabbit rhinovirus antisera depended on production of immunogens with virus concentrations of at least 107 pfu/ml. Response in pairs of rabbits immunized with the same antigen appeared to be remarkably uniform, and maximum antibody titers were attained at 38 to 45 days after beginning a relatively simple ...
George E. Kenny, Marion K. Cooney
openaire +3 more sources
Immunogenicity of TNF-Inhibitors [PDF]
Frontiers in Immunology, 2020 Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either primary or secondary failure to TNFi due to ineffectiveness of the drug or adverse reactions.
Sadaf Atiqi +5 more
openaire +4 more sources